Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Vanda Pharmaceuticals, Inc. (NQ: VNDA)
6.580 USD  +1.080 (+19.64%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Vanda Pharmaceuticals, Inc.
 
< Previous 1 2 3 4 5 6 Next >
Tech Council of Maryland Announces Winners of 2013 Tech Awards at Annual Dinner and Celebration
May 17, 2013
from Business Wire News Releases
Vanda Pharmaceuticals Reports First Quarter 2013 Results
May 09, 2013
from PR Newswire
Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
April 18, 2013
Conference Call and Webcast to Follow Read More
from PR Newswire
Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
April 17, 2013
from PR Newswire
Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
April 04, 2013
Presentation will be Webcast Live and Archived on Vanda's Website Read More
from PR Newswire
Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
March 25, 2013
from PR Newswire
Programs by the FDA Designed to Speed Up Approval Process for Critical Drugs a Key Factor in Biotech's Industry Success
March 18, 2013
Five Star Equities Provides Stock Research on ArQule and Vanda Pharmaceuticals Read More
from Marketwired News Releases
Vanda Withdraws Its Marketing Authorization Application For Fanaptum™ In The European Union
March 14, 2013
from PR Newswire
Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
February 27, 2013
Presentation will be Webcast Live and Archived on Vanda's Website Read More
from PR Newswire
Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
February 12, 2013
from PR Newswire
Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
January 31, 2013
from PR Newswire
Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
January 23, 2013
-- Tasimelteon significantly maintains entrainment of circadian rhythms Read More
from PR Newswire
Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
January 22, 2013
Conference Call and Webcast to Follow Read More
from PR Newswire
The Reason It Trades, What's Moving DNDN, VNDA, LFVN and ALXA
December 20, 2012
from Marketwired News Releases
Free Research Reports on ARNA, GPOR, SWHC and VNDA Issued by the Bedford Report
December 19, 2012
Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT Read More
from Marketwired News Releases
The Real Story Behind VNDA, MEIP, SNFCA and LINC
December 19, 2012
from Marketwired News Releases
Vanda Announces Positive Phase III Results For Tasimelteon In The Treatment Of Non-24-Hour Disorder
December 18, 2012
-- Tasimelteon is shown to entrain the master body clock as measured by melatonin and cortisol circadian rhythms Read More
from PR Newswire
Vanda Receives Negative Opinion from CHMP on Fanaptum™ for the Treatment of Schizophrenia
December 13, 2012
from PR Newswire
Vanda Pharmaceuticals Reports Third Quarter 2012 Results
November 07, 2012
from PR Newswire
Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
November 05, 2012
Presentation will be Webcast Live and Archived on Vanda's Website Read More
from PR Newswire
Vanda Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 7, 2012
October 17, 2012
Conference Call and Webcast to Follow Read More
from PR Newswire
Tasimelteon Restores Daily Cortisol Rhythms in Blind Patients with Non-24-Hour Disorder
October 15, 2012
from PR Newswire
Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
August 23, 2012
Presentations will be Webcast Live and Archived on Vanda's Website Read More
from PR Newswire
Fanapt™ is Granted Market Approval in Israel for the Treatment of Schizophrenia
August 09, 2012
from PR Newswire
Vanda Pharmaceuticals Reports Second Quarter 2012 Results
August 02, 2012
from PR Newswire
Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
July 10, 2012
Conference Call and Webcast to Follow Read More
from PR Newswire
Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
July 05, 2012
Presentation will be Webcast Live and Archived on Vanda's Website Read More
from PR Newswire
Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
June 18, 2012
from PR Newswire
Seventy Percent of Totally Blind Individuals With Sleep Complaints Suffer From Chronic Circadian Rhythm Sleep Disorder
June 11, 2012
Vanda presents new data at SLEEP 2012 26th Annual Meeting of the Associated Professional Sleep Societies Read More
from PR Newswire
Vanda Pharmaceuticals to Present at SLEEP 2012 26th Annual Meeting of the Associated Professional Sleep Societies
June 04, 2012
from PR Newswire
< Previous 1 2 3 4 5 6 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here